A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub -study SWOG S1400C.

被引：8
|
作者：
Edelman, Martin J.
Redman, Mary Weber
Albain, Kathy S.
McGary, Eric C.
Rafique, Norman
Petro, Daniel P.
Waqar, Saiama Naheed
Miao, Jieling
Griffin, Katie
Papadimitrakopoulou, Vassiliki
Kelly, Karen
Gandara, David R.
Herbst, Roy S.
机构：
[1] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[2] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[3] Loyola Univ, Chicago Stritch Sch Med, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA
[4] Kaiser Permanente, Cadillac, CA USA
[5] Tricty Hematol Oncol Associates, Mercy Med Ctr, Massilon, OH USA
[6] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA
[7] Washington Univ, Div Oncol, Dept Med, Sch Med, St Louis, MO USA
[8] Fred Hutchinson Canc Res Ctr, SWOG Stat Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[10] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA 95817 USA
[11] Univ Calif Davis, Sacramento, CA 95817 USA
[12] Yale Sch Med, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.9056
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9056
引用
收藏
页数：5
相关论文
共 50 条
  • [1] SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
    Edelman, Martin J.
    Redman, Mary W.
    Albain, Kathy S.
    McGary, Eric C.
    Rafique, Noman M.
    Petro, Daniel
    Waqar, Saiama N.
    Minichiello, Katherine
    Miao, Jieling
    Papadimitrakopoulou, Vassiliki A.
    Kelly, Karen
    Gandara, David R.
    Herbst, Roy S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : 1853 - 1859
  • [2] SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)
    Borghaei, Hossein
    Redman, Mary W.
    Kelly, Karen
    Waqar, Saima N.
    Robert, Francisco
    Kiefer, Gauri J.
    Stella, Philip J.
    Minichiello, Katherine
    Gandara, David R.
    Herbst, Roy S.
    Papadimitrakopoulou, Vassiliki A.
    CLINICAL LUNG CANCER, 2021, 22 (03) : 178 - 186
  • [3] A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B.
    Wade, James Lloyd
    Langer, Corey J.
    Redman, Mary
    Aggarwal, Charu
    Bradley, Jeffrey D.
    Crawford, Jeffrey
    Miao, Jieling
    Griffin, Katie
    Herbst, Roy S.
    Kelly, Karen
    Gandara, David R.
    Papadimitrakopoulou, Vassiliki
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
    Langer, Corey J.
    Redman, Mary W.
    Wade, James L., III
    Aggarwal, Charu
    Bradley, Jeffrey D.
    Crawford, Jeffrey
    Stella, Philip J.
    Knapp, Mark H.
    Miao, Jieling
    Minichiello, Katherine
    Herbst, Roy S.
    Kelly, Karen
    Gandara, David R.
    Papadimitrakopoulou, Vassiliki A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : 1839 - 1846
  • [5] A phase II study of durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP Substudy SWOG S1400A
    Papadimitrakopoulou, V.
    Redman, M. W.
    Borghaei, H.
    Waqar, S. N.
    Robert, F.
    Kiefer, G. J.
    McDonough, S.
    Herbst, R. S.
    Kelly, K.
    Gandara, D. R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753).
    Waqar, Saiama Naheed
    Redman, Mary Weber
    Arnold, Susanne M.
    Hirsch, Fred R.
    Mack, Philip C.
    Schwartz, Lawrence Howard
    Gandara, David R.
    Stinchcombe, Tom
    Leighl, Natasha B.
    Ramalingam, Suresh S.
    Tanna, Saloni H.
    Raddin, Ryan S.
    Minichiello, Katherine
    Kelly, Karen
    Bradley, Jeffrey D.
    Herbst, Roy S.
    Papadimitrakopoulou, Vassiliki
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)
    Waqar, Saiama N.
    Redman, Mary W.
    Arnold, Susanne M.
    Hirsch, Fred R.
    Mack, Philip C.
    Schwartz, Lawrence H.
    Gandara, David R.
    Stinchcombe, Thomas E.
    Leighl, Natasha B.
    Ramalingam, Suresh S.
    Tanna, Saloni H.
    Raddin, Ryan S.
    Minichiello, Katherine
    Bradley, Jeffrey D.
    Kelly, Karen
    Herbst, Roy S.
    Papadimitrakopoulou, Vassiliki A.
    CLINICAL LUNG CANCER, 2021, 22 (03) : 170 - 177
  • [8] A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G).
    Owonikoko, Taofeek Kunle
    Redman, Mary Weber
    Byers, Lauren Averett
    Hirsch, Fred R.
    Mack, Philip C.
    Schwartz, Lawrence Howard
    Bradley, Jeffrey D.
    Stinchcombe, Tom
    Leighl, Natasha B.
    Al Baghdadi, Tareq
    Lara, Primo
    Miao, Jieling
    Kelly, Karen
    Ramalingam, Suresh S.
    Herbst, Roy S.
    Papadimitrakopoulou, Vassiliki
    Gandara, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).
    Leighl, Natasha B.
    Redman, Mary Weber
    Rizvi, Naiyer A.
    Hirsch, Fred R.
    Mack, Philip C.
    Schwartz, Lawrence Howard
    Wade, James Lloyd
    Irvin, William Johnson
    Reddy, Sreekanth
    Crawford, Jeffrey
    Bradley, Jeffrey D.
    Stinchcombe, Tom
    Ramalingam, Suresh S.
    Miao, Jieling
    Minichiello, Katherine
    Gandara, David R.
    Herbst, Roy S.
    Papadimitrakopoulou, Vassiliki
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952).
    Bazhenova, Lyudmila
    Redman, Mary Weber
    Gettinger, Scott N.
    Hirsch, Fred R.
    Mack, Philip C.
    Schwartz, Lawrence Howard
    Gandara, David R.
    Bradley, Jeffrey D.
    Stinchcombe, Tom
    Leighl, Natasha B.
    Ramalingam, Suresh S.
    Tavernier, Susan S.
    Minichiello, Katherine
    Kelly, Karen
    Papadimitrakopoulou, Vassiliki
    Herbst, Roy S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345